Fortitude Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Fortitude Family Office’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$35.6K	Buy	47 +19	+68%	+$14.4K	0.01%	590
2026 Q2	$17.5K	Buy	28 +3	+12%	+$2.04K	﹤0.01%	571
2026 Q1	$19.3K	Buy	25 +14	+127%	+$10.7K	﹤0.01%	439
2025 Q4	$8.49K	Sell	11 -4	-27%	-$2.72K	﹤0.01%	632
2025 Q3	$8.43K	Sell	15 -3	-17%	-$1.7K	﹤0.01%	626
2025 Q2	$9.45K	Sell	18 -36	-67%	-$20.1K	﹤0.01%	577
2025 Q1	$34.2K	Hold	54	–	–	0.01%	290
2024 Q4	$38.5K	Sell	54 -2	-4%	-$1.68K	0.01%	304
2024 Q3	$58.9K	Hold	56	–	–	0.02%	218
2024 Q2	$58.9K	Buy	56 +21	+60%	+$20.4K	0.03%	156
2024 Q1	$33.7K	Hold	35	–	–	0.02%	199
2023 Q4	$30.7K	Buy	+35	New	+$28.8K	0.02%	230

Other funds holding REGN

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Fortitude Family Office's REGN Position: Q3 2026 in Review

Fortitude Family Office increased its Regeneron Pharmaceuticals (REGN) stake by 68% in Q3 2026, buying an estimated $14.4K and bringing the position to 47 shares worth $35.6K. The position accounts for 0.01% of the portfolio, ranked #590.

Fortitude Family Office first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $58.9K in Q3 2024. 151 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Fortitude Family Office held 47 shares of Regeneron Pharmaceuticals worth $35.6K as of Q3 2026.
Fortitude Family Office bought 19 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $14.4K.
Regeneron Pharmaceuticals made up 0.01% of Fortitude Family Office's portfolio in Q3 2026, its #590 holding.
Fortitude Family Office first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
Fortitude Family Office's Regeneron Pharmaceuticals position peaked at $58.9K in Q3 2024.
151 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.